Qlosi Eye Drops for Presbyopia Linked to Stable Optical Sales, Study Finds

A study presented at Optometry’s Meeting in Phoenix found that prescribing Qlosi (pilocarpine ophthalmic solution 0.4%) for presbyopia did not reduce optical purchases or negatively impact practice performance metrics, according to Harmin J. Chima, OD, FAAO, vice president of professional services at West Point Optical Group.

What Impact Do Qlosi Eye Drops Have on Optical Sales?

The research, conducted in collaboration with Orasis Pharmaceuticals, analyzed 111 participants across eight locations. Results showed that 71.6% of patients prescribed Qlosi purchased optical lenses, compared to 68.8% in the practice’s corporate baseline. “The presbyopia drop did not cannibalize optical sales,” Chima said. “The comprehensive nature of the visit reinforced the value of optical correction.”

How Did Practice Metrics Change During the Study?

Other key performance indicators improved or remained stable. New medical diagnoses rose to 24.5% from 18.3%, and ultra-widefield imaging usage increased to 85.6% from 69.2%. Alan G. Kabat, OD, FAAO, medical director at Orasis Pharmaceuticals, attributed the shift to patient receptiveness. “Patients open to trying new treatments were more engaged with the examination process,” he noted.

Why Does This Matter for Optometric Practices?

The findings challenge concerns that presbyopia treatments like Qlosi might undermine traditional revenue streams. Kabat emphasized that “Qlosi is not a threat but an asset” to optometric practices. The study, funded by Orasis Pharmaceuticals, aligns with broader efforts to integrate innovative therapies without compromising patient care or financial stability.

What Are the Broader Implications for Presbyopia Treatment?

Presbyopia, a common age-related condition, affects nearly 1.8 billion people globally. While corrective lenses remain the standard, drop-based therapies like Qlosi offer alternative options. The study’s results suggest that practices can adopt such treatments without sacrificing optical sales, potentially expanding patient choice and engagement.

For more details, refer to the study published in Healio.